Regarding the increase in the risk for thromboembolic events [23, 27], it must be taken into account specially in patients with cardiovascular disease, in whom the ESA dose must be adjusted according to patient characteristics to avoid an excessive change in plasma volume and maintaining a consistent Hb level [28]. The gene discussed is GSTM1; the disease is cardiovascular disorder.